by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
